ArticleDermatology practical & conceptual2026
Comparative Study on the Therapeutic Efficacy of Topical Bimatoprost (0.03%) Ophthalmic Solution and Tacrolimus (0.1%) Ointment in Stable Vitiligo.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitiligo is a chronic autoimmune skin disorder characterized by loss of melanocytes, leading to depigmented patches. Although not associated with physical morbidity, its appearance causes significant psychological distress, especially in dark-skinned individuals. Tacrolimus, a topical calcineurin inhibitor, is first-line treatment for localized, stable vitiligo. However, bimatoprost, a prostaglandin analog known for its melanin-stimulating activity, is emerging as a potential alternative.
objectivesPRIMARY
objectiveTo compare the efficacy of topical bimatoprost 0.03% ophthalmic solution versus tacrolimus 0.1% ointment in stable vitiligo. SECONDARY
objectiveTo evaluate the clinical response of bimatoprost 0.03% ophthalmic solution versus tacrolimus 0.1% ointment and to assess their safety and adverse effects in stable vitiligo. MATERIAL &
methodsA randomized comparative study was conducted over 24 months in the Department of Dermatology at Era's Lucknow Medical College. Fifty clinically stable vitiligo patients (aged >18 years, <5% BSA involvement) were randomized into two groups: Group A received topical bimatoprost 0.03%, and Group B received topical tacrolimus 0.1%, both applied twice daily over the lesions. Treatment was continued for 12 weeks, with follow-up every four weeks. Efficacy was assessed using the Vitiligo Area Scoring Index (VASI), subjective score, and photographic documentation. Any side effect was documented at each follow-up.
resultsBoth groups showed clinical improvement, with Group A demonstrating faster onset of repigmentation, particularly in facial lesions. Bimatoprost was well tolerated, with minimal side effects such as local hypertrichosis, while tacrolimus was associated with mild burning sensation in some cases.
conclusionTopical bimatoprost 0.03% is a safe and effective alternative to tacrolimus 0.1% ointment in treating stable vitiligo, especially for cosmetically sensitive areas. Therefore, it can be considered as a treatment option in stable vitiligo.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.